Join
Live feed
·
PRReleasevia Quantisnow
Vaxcyte Inc. logo

Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies

ByQuantisnow·Wall Street's wire, on your screen.
PCVX· Vaxcyte Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PCVX (Vaxcyte Inc.) and more on Quantisnow.